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AbstractThe problem with detecting adverse drug reactions (ADRs)
from drugs is that they may not be obvious until long after they are
widely prescribed. Part of the problem is these events are rare. This
work describes an approach to signal detection of ADRs based on
association rules (AR) in Australian drug safety data. This work was
carried out using the Australian Adverse Drug Reactions Advisory
Committee (ADRAC) database, which contains a hundred and thirty
seven thousand records collected in 1972-2001 period.
Many signal detection methods have been developed for drug
safety data, most of which use a classical statistical approach. Some
of these stratify the data using an ontology for reactions, but the
application of drug ontologies to ADR signal detection methods has
not been reported.
We propose a novel approach for detecting various signal levels by
using an overlapped windowing approach. The overlapping windows
help to detect smooth transition of signal. We use association rules
for measuring signiﬁcant change over time for different hierarchical
levels of drugs (using the Anatomical-Therapeutic-Chemical (ATC)
system of drug classiﬁcation ontology) and their reactions based
on the System Organ Classes (SOC) ontology. Using association
rules and their strength for different levels in the drug and reaction
hierarchy, helps in the detection of signals at particular levels in
higher order using a bottom up approach.
The results of a preliminary investigation of ADRAC data using
our method demonstrate that this approach could produce a powerful
and robust ADR signal detection method.
I. INTRODUCTION
Post-marketing safety databases are large, sparse, full of
biased, uncontrolled and incomplete data [1]. The detection
of unknown and unexpected connections between drug ex-
posure and adverse events (AEs) is one of the major chal-
lenges of pharmacovigilance. For the identiﬁcation of possible
connections in large databases, automated statistical systems
have been introduced with promising results. From the large
numbers of associations so produced, the human mind has to
identify signals that are likely to be important, in need of fur-
ther assessment and follow-up and that may require regulatory
action [2]. Many approaches have been tried for the analysis of
adverse reaction data, such as: Fisher’s Exact Test and matched
pair designs (McNemar’s test) [3], Reporting Odds Ratio
(ROR), and Yule’s Q [4]. Recently, regulatory authorities,
drug monitoring centers, and pharmaceutical companies, have
directed more attention to the development, implementation ,
and deployment of computer-assisted signal detection systems.
The three most commonly used methods with the greatest
published experience are: proportional reporting ratios (PRRs)
[5], [6], an application of empiric Baysean screening (EBS)
known as the mulit-item gamma Poisson shrinker (MGPS)
[6], [7], [8], and the Bayesian conﬁdence propagation neural
network (BCPNN) [6], [9].
The Australian Adverse Drug Reaction Advisory Committee
(ADRAC) database has been developed and maintained by
the Therapeutic Goods Administration (TGA) with the aim to
detect signals from adverse drug reactions (ADRs) as early
as possible. The ADRAC data contain 137,297 voluntarily
reported adverse drug reaction records involving 5057 different
drugs, based on the ‘drug dictionary’ used by ADRAC of 7416
available drug terms, and 868 different reactions, based on
1392 available reaction terms. There are many ﬁelds in the
ADRAC database, including report date and ﬁelds containing
drug and reaction terms. There are two groups of ten ﬁelds,
which are allocated for drug terms and reaction terms. A more
detailed account of the ADRAC database is given in [10].
A. Data Consolidation
The biggest challenge in summarizing safety data is the need
to consolidate the massive amount of data into a manageable
format. One way is to group the safety data into K classes
characterized by body systems and determined in conjunction
with underlying disease and treatments involved. Such pooling
of data through coding is especially helpful for rare events
[11], [12]. The World Health Organization (WHO) maintains
such a classiﬁcation of reaction terms [13]. These are groups
of adverse reaction preferred terms pertaining to the same
systems organ class (SOC). The Australian drug safety data
maintained by ADRAC uses WHO ADR terms and SOC
grouping; see [10], [14], [15]. For more details of SOC
information in ADRAC see [16].
There has been a need for a similar kind of grouping to
apply to drugs in the ADRAC data, which are currently listed
by trade name [15]. In these data, some of these trade names
were assigned anatomical-therapeutic-chemical classiﬁcation
(ATC) codes by ADRAC, but in cases where the trade name
had more than one ingredient, ATC codes were not assigned.
This paper applies an ad hoc classiﬁcation made by us [16]
where each trade name code was assigned a corresponding
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ATC code. The classiﬁcation system implemented was the
WHO Collaborating Centre for Drug Statistics Methodology
ATC codes in order to enable: (i) the grouping of the same
substance into one code, and (ii) the grouping of related
substances into more general categories. To this purpose the
ATC codes for drugs have been purchased by us from Ms
Kirsten Myhr, RELIS Øst, Ulleva˝l University Hospital, 0407
OSLO (http://www.whocc.no/).
B. ATC embedded code
The ATC encoding system implements an an embedded
encoding system, which employs a seven character coding
system. As an example, the ﬁrst member of the system will
be used. The level we call level 0, the character is ‘A’, the
level 1 is ‘A01’, level 2 is ‘A01A’, level 3 is ‘A01AA’ and
level 4 is ‘A01AA01’. The embedded coding can be utilized
to simplify database queries and algorithm coding. Employing
this embedded coding, which resides in the ATC code string,
can be now utilized to aggregate the data at the required level.
C. Classiﬁcation of ADRAC data for this analysis
For the purposes of this present investigation, in cases
where the original drug code had more than one ingredient, a
unique code was assigned from ATC codes for combinations
of ingredients. This was done in order to preserve a one-to-
one correspondence between original drug codes and the ATC
codes facilitating comparison of the two drug classiﬁcation
schema. This resulted in 1806 ATC drug terms from the 5081
drug trade name terms. There are ﬁve levels of classes in the
ATC system: level 0 had 14 classes, level 1 had 95, level 2
had 217, level 3 had 581 and level 4 had 1785.
D. Critical Terms
From the third quarter of 1998, a new ﬁeld has been added at
the end of the WHO-ART ﬁle which indicates Critical Terms.
Critical terms are a subset of adverse reaction terms referring
to, or possibly being indicative of, serious disease states, which
have been regarded as particularly important to follow up. [13],
[17] This is a very important component of expert knowledge,
which can be incorporated into the ADR signal detection.
In this report we weight critical reaction terms to highlight
associations which are likely to be of greater interest and
particularly those that are rare.
E. Motivation
Automated signal detection and data mining techniques
are evolving rapidly, but several outstanding issues remain
problematic. These include the absence of a gold standard
against which to evaluate signal detection methods, lack of
validation and comprehensive head-to-head comparisons of
the various methods, lack of transparency of the Bayesian-
based methods, lack of best practices or recommended data
mining protocols, the inﬂuence of AE dictionary structure on
performance characteristics, limited speciﬁcity, and potential
for misapplication of these techniques [18]. In one study there
were 136 relevant DECs that triggered safety-related labelling
changes for 39 drugs during a 7-month period. PRRs generated
a signal of disproportionate reporting with almost twice as
many drug-event combinations (DECs) as MGPS (77 versus
40). DECs generating signals of disproportionate reporting
with only PRRs were both medically serious and non-serious.
No medically important events were signalled by MGPS only
[19]. Other difﬁculties with MGPS are “signal leakage”, in
which a signal truly associated with drug A may manifest
as an apparent signal with drug B due to the fact that the
two drugs are frequently co-prescribed, and “signal masking”,
whereby a signal for drug A can be diminished in magnitude if
drug B has a very dominant signal in the database [20]. Some
of the logic (for example triage logic) for signal selection and
follow-up are discussed in relation to UMC data by Meyboom
et al. [2] and Sta˚hl et al. [21], [22]. Therefore there is still
more work to be done in the ADR signalling methodology.
II. METHOD AND RESULTS
A. Aim
The aim of this paper is to present the developments in our
approach to developing an ADR signalling method. We use the
SOC reaction term and ATC drug term hierarchies to establish
drug-reaction associations, by traversal of the ATC tree where
reaction frequencies are signiﬁcant (based on Chi-Square –
χ2). The algorithm then surveys the temporal reporting of
these reactions using a varying time window, which smooths
monthly variation and seeks to ﬁnd frequent associations (also
using the χ2 test) of a critical nature. The algorithm then
generates a report on the signal status of this reaction set.
B. Research Methodology
1) The association between drug/class and reactions:
Among many different techniques used to extract useful
knowledge from databases, Association Rule mining, has in
recent years, attracted the attention of data mining communi-
ties [23]. Association rule mining is a form of data mining used
to discover interesting relationships amongst two or more at-
tributes in data. Association rules were introduced by Agrawal
et al. [23] and originated with the problem of supermarket
basket analysis. In basket analysis association rules were used
to ﬁnd associations between the items bought by a customer in
order to ﬁnd which items were frequently bought together. The
ﬁndings can be used to understand customers’ buying habits
and preferences in order to increase proﬁts.
An association rule is an expression of the form X ⇒ Y
[support, conﬁdence], where X and Y are sets of items that
are often found together in a given collection of data. The
attribute group on the left hand side of the arrow is called
the antecedent or “left hand side” (LHS) and the group of
attributes on the right hand side of the arrow is called the
consequent or “right hand side” (RHS). While association
rules have proven to be useful in practical applications, AR
algorithms tend to generate large numbers of rules, most of
which are of little interest. In order to ﬁlter uninteresting rules
the interesetingness and usefulness of an association rule has
been based on user deﬁned support and conﬁdence thresholds.
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If both support and conﬁdence values are greater than the
threshold, the association rule is considered interesting. The
support is the percentage of rows in the database containing
both X and Y. In this study we do not use support as a
measure of interestingness because higher support will ﬁlter
out rare associations. In many real life applications some
items appear frequently in the data, while others rarely
appear. If we use support as a measure of interesetingness
those rules that involve rare items will not be found. The
conﬁdence is the conditional probability of Y given X, for
example, conﬁdence = P (Y | X) .
Our method seeks to ﬁnd if there exists any association
between any particular drug or drug class and a set of critical
reactions using a tree structure. For example an association
rule R1 drug = M01AH01 ⇒ reaction = 636 [conﬁdence
35%] means that 35% of patients who took drug M01AH01
(Celecoxib) had reaction with code 636 (hypertension). This
association can also be represented as conditional probability
P (reaction = 636 | drug = M01AH01)
In this study the traditional AR approach is not directly
used. We organize generated association rules by separating
the discovered rules into rule sets. Each rule set contains as-
sociation rules that share a common consequent. For example
association rules drug = M01⇒ cardiovascular reactions and
drug = M02 ⇒ cardiovascular reactions represent a rule set
because they share the same consequent.
We generate the tree using a breadth ﬁrst search. The root
of the tree denotes the top drug class level (for example, M)
and children nodes denote a subclass of the parent node (for
example, M01, M02 and M03) and leaves denote a particular
drug (for example, M01AH01). During traversal of the tree we
ﬁnd if another level of the tree needs to be generated according
to our convergence criteria. The details of our algorithm are
as follows:
Step 1. We select the top drug class and and a reaction class
of interest. For example we select drug class M and reaction
class – cardiovascular reactions (SOC1000) .
Step 2. We generate the next level of the drug class as
child nodes of the tree. We ﬁnd the set of children for the
drug classes that are associated with the selected reaction
class. For example for drug class M we ﬁnd children M01,
M02, M03 and M04 and then for each child we generate
group of association rules for class – cardiovascular reactions
(SOC1000).
R1 drug = M01 ⇒ cardiovascular reactions [conf]
R2 drug = M02 ⇒ cardiovascular reactions [conf]
R3 drug = M03 ⇒ cardiovascular reactions [conf]
R4 drug = M04 ⇒ cardiovascular reactions [conf]
If the discrepancy between the conﬁdence values of these
association rules is substantially high, this group is considered
different on the basis of cardiovascular reactions, otherwise the
group is considered similar. If the group is considered different
by using the χ2 test we ﬁnd if there is a signiﬁcant difference
in frequencies. We generate a contingency table containing
frequencies and calculate the chi-square value If we ﬁnd
Fig. 1. Tree traversal of signal algorithm.
signiﬁcant differences we choose child(ren) with maximum
frequency. Figure 1 illustrates breadth search steps.
Figure 1 depicts such a traversal. For example, if drug
class M is chosen, the children M01, M02, M03, M04,
M05, M09 are examined. M01 is found to be signiﬁcant,
so its children, M01A, M01B, M01C, are examined. M01A
is found to be signiﬁcant, so its children, M01AA, M01AB,
M01AC, M01AE, M01AG, M01AH, M011AX are examined.
M01AH is found to be signiﬁcant, so its children, M01AH01,
M01AH02 are examined. M01AH01 (see Figure 2, where
reaction class SOC1000 was chosen) is found to be signiﬁcant.
The algorithm terminates at this leaf.
Step 3. We continue the above step 2 until:
• the lowest level of drug class is found or,
• χ2 test fails. This means that this particular drug class
level is responsible for the reactions
Once search process terminates we generate association
rules for drug(s) and adverse reactions. A drug can be either
drug class (for example, M01AH) or drug (for example,
M01AH01). Adverse reactions (ADR) are reactions belonging
to the same reaction class. For example ADR 67, 68,104
belong to cardiovascular reaction class (SOC1000) as
illustrated in Figure 2. Association rules displayed in Figure 2
are used for descriptive purposes. For examplethe highest bar
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in this ﬁgure shows that almost 15% of patients taking drug
M01AH01 with cardiovascular reactions had experienced
ADR 636 ( hypertension ). This ﬁnding could be represented
as an association rule drug = M01 AND cardiovascular
reactions ⇒ hypertension [conf 14%]
2) Generating signals using overlapping time windowing
approach: Once an association between a particular drug and
a set of signiﬁcant reaction classes has been found from above,
we plot the frequency of the signiﬁcant reaction classes over
time. A time window length of 3 has been considered with a
phase shift of 1 time interval. This overlapping time window
with a sift helps to smooth the signals. For each time frame
we use χ2 test to ﬁnd the signals which indicates sudden
increase in number of reactions. Depending on the percentage
of critical terms reported from time of signal back to the
start time, we label the signal. Six different types of signals –
OK (15% or below), notice (between 15% and 30% ), strong
notice (between 30% and 40%), warning (between 40% and
50%), strong warning (between 50% and 60%), Alert(60% or
above). Furthermore we look at the support of frequencies of
all reactions from time of start to time of signal.
C. Experimental Results
1) Drugs giving strong signals: Celebrex and cardiovas-
cular (SOC 1000)
The output if drug M01AH01 and cardiovascular reactions
are selected, the histogram in Figure 2 is displayed and the
following output is made:
“Cardiovascular system reactions for drug M01AH01 Cele-
coxib (total of 282 reactions)
1) Celecoxib (M01AH01) makes 1.952) 22.18% (593 cases)
of patients taking Celecoxib had CRITICAL reactions overall
3) 77.82% (2080 cases) of patients taking Celecoxib had
NON CRITICAL reactions overall 4) 43.62% (123 cases) of
patients taking Celecoxib with Cardiovascular system reac-
tions - CRITICAL and they make 4.60 of all patients taking
Celecoxib 5) 56.38% (159 cases) of patients taking Celecoxib
with Cardiovascular system reactions - NON CRITICAL and
they make 5.95 of all patients taking Celecoxib”
“Cardiovascular system - reaction monthly counts for drug
M01AH01 - Celecoxib (total:282 for 22 months)”
Monthly counts are given in Figure 3.
“Null hypothesis: There are no ADR signals in this time
span is REJECTED WARNING (46.27% critical and 53.73%
non critical reactions (out of 67) before the signal on 200002)
(position 4)”
Overlapping window counts are given in Figure 4.
“Null hypothesis: There are no ADR signals in this time
span is REJECTED High Frequency WARNING (42.42%
critical and 57.58% non critical reactions (out of 231) before
the signal on 200011)”
Heparin and haemic and lymphatic system (SOC 1200)
The output if drug B01AB01 and haemic and lymphatic
system reactions are selected, the histogram in Figure 5 is
displayed and the following output is made:
Fig. 2. Celecoxib (M01AH01) cardiovascular reactions (SOC1000).
“Haemic and lymphatic systems reactions for drug
B01AB01 Heparin (total of 220 reactions)
Heparin (B01AB01) makes 0.53% ( cases) of all records
(out of 137279) 2) 37.15% (269 cases) of patients taking Hep-
arin had CRITICAL reactions overall 3) 62.85% (455 cases) of
patients taking Heparin had NON CRITICAL reactions overall
4) 87.27% (192 cases) of patients taking Heparin with Haemic
and lymphatic systems reactions - CRITICAL and they make
26.52 of all patients taking Heparin 5) 12.73% (28 cases) of
patients taking Heparin with Haemic and lymphatic systems
reactions - NON CRITICAL and they make 3.87 of all patients
taking Heparin”
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Fig. 3. Celecoxib (M01AH01) cardiovascular reactions (SOC1000) –
monthly reactions.
The most frequent reaction, THROMBOCYTOPENIA
(1243) 160 cases severity 10.
“Haemic and lymphatic systems - reaction monthly counts
for drug B01AB01 - Heparin (total:220 for 123 months)
Null hypothesis: There are no ADR signals in this time
span is REJECTED ALERT (88.64% critical and 11.36% non
critical reactions (out of 44) before the signal on 198612)
(position 24)”
Overlapping window counts are given in Figure 6.
“Overlapping Time Window (X3) for Haemic and lymphatic
systems - 121 time slots drug B01AB01 - Heparin
Fig. 4. Celecoxib (M01AH01) cardiovascular reactions (SOC1000) –
overlapping window reactions.
Null hypothesis: There are no ADR signals in this time span
is REJECTED Very low frequency ALERT (86.67% critical
and 13.33% non critical reactions (out of 180) before the signal
on 199807)”
2) Drug giving weak signals: Paracetamol and cardio-
vascular (SOC 1000)
The output if drug N02BE01 and cardiovascular reactions
are selected, the histogram in Figure 7 is displayed and the
following output is made:
“Cardiovascular system reactions for drug N02BE01 Parac-
etamol (total of 20 reactions)
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Fig. 6. Heparin (B01AB01) Haemic and lymphatic systems reactions (SOC1200) – overlapping window reactions.
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Fig. 5. Heparin (B01AB01) Haemic and lymphatic systems reactions
(SOC1200).
1) Paracetamol (N02BE01) makes 0.25% ( cases) of all
records (out of 137279) 2) 22.81% (78 cases) of patients taking
Paracetamol had CRITICAL reactions overall 3) 77.19% (264
cases)of patients taking Paracetamol had NON CRITICAL
reactions overall 4) 25.00% (5 cases)of patients taking Parac-
etamol with Cardiovascular system reactions - CRITICAL and
they make 1.46 of all patients taking Paracetamol 5) 75.00%
(15 cases) of patients taking Paracetamol with Cardiovascular
system reactions - NON CRITICAL and they make 4.39 of
all patients taking Paracetamol
Null hypothesis: There are no ADR signals in this time span
Fig. 7. Paracetamol (N02BE01) cardiovascular reactions (SOC1000).
is ACCEPTED No SIGNAL”
Paracetamol and Haemic and lymphatic systems (SOC
1200)
The output if drug N02BE01 and haemic and lymphatic
systems reactions are selected, the histogram in Figure 8 is
displayed and the following output is made:
“Haemic and lymphatic systems reactions for drug
N02BE01 Paracetamol (total of 11 reactions)
1) Paracetamol (N02BE01) makes 0.25% ( cases) of all
records (out of 137279) 2) 22.81% (78 cases) of patients taking
Paracetamol had CRITICAL reactions overall 3) 77.19% (264
cases) of patients taking Paracetamol had NON CRITICAL
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Fig. 8. Paracetamol (N02BE01) haemic and lymphatic systems reactions
(SOC1200).
reactions overall 4) 27.27% (3 cases) of patients taking Parac-
etamol with Haemic and lymphatic systems reactions - CRIT-
ICAL and they make 0.88 of all patients taking Paracetamol 5)
72.73% (8 cases) of patients taking Paracetamol with Haemic
and lymphatic systems reactions - NON CRITICAL and they
make 2.34 of all patients taking Paracetamol
Non-sliding windows graph Haemic and lymphatic systems
- reaction monthly counts for drug N02BE01 - Paracetamol
(total:11 for 11 months)
Null hypothesis: There are no ADR signals in this time span
is ACCEPTED
NO SIGNAL”
III. DISCUSSION
In this paper we have presented case studies that illustrate
the way in which the ontologies and the ADR signal detection
approach work hand in hand to allow a user to understand at
each level of the tree what may be involved in an adverse
reaction to a drug or drug class. We chose examples of drugs
that illustrated where a known signal is detected in particular
reaction classes and one drug were a signal should not be
detected and indeed is not, for the reaction classes in which
the other two drugs gave signals. These examples show that
the method behaves as expected. More extensive testing and
reﬁnement of this method is planned.
IV. CONCLUSION
The ATC ontology enables pooling of all data relating
to a single ingredient, rather than having it split between
different trade names. without this, the straight application of
association rules would not be useful. Our approach provides
a means for reducing the computation of all association rules
and trying to ﬁlter them. This approach is stepwise meaningful
because the ontologies provide meaning. The fact that there
are several levels of granularity in this classiﬁcation allows
analysis at different levels. We have demonstrated that, using
the ATC and SOC ontologies our association rule methods can
explore even very rare associations in the ADRAC data. The
tree structure of the ATC ontology was exploited to develop
an adverse event signalling method that can ‘drill down’
the ATC tree to ﬁnd individual drugs that have signiﬁcantly
more reactions in a given SOC. Then, using the critical
term ontology, monthly reaction frequencies are examined to
produce warnings when reactions rise to a signiﬁcant level.
A time windowing approach was used to smooth reaction
frequencies. Thus the application of ontologies to drug safety
data enables a signiﬁcant advance in adverse event signalling
methodology.
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